Vascular complications following intra-aortic balloon pump implantation: an updated review by de Jong, Monique M. et al.
Open Research Online
The Open University’s repository of research publications
and other research outputs
Vascular complications following intra-aortic balloon
pump implantation: an updated review
Journal Item
How to cite:
de Jong, Monique M.; Lorusso, Roberto; Al Awami, Fatima; Matteuci, Francesco; Parise, Orlando; Lozekoot,
Pieter; Bonacchi, Massimo; Maessen, Jos G.; Johnson, Daniel M. and Gelsomino, Sandro (2018). Vascular
complications following intra-aortic balloon pump implantation: an updated review. Perfusion, 33(2) pp. 96–104.
For guidance on citations see FAQs.
c© 2017 The Author(s)
Version: Version of Record
Link(s) to article on publisher’s website:
http://dx.doi.org/doi:10.1177/0267659117727825
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
https://doi.org/10.1177/0267659117727825
Perfusion
2018, Vol. 33(2) 96 –104
© The Author(s) 2017
Reprints and permissions: 
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1 77/0267 591 7 278
journals.sagepub.com/home/prf
Introduction
The intra-aortic balloon pump (IABP) is one of the 
most commonly used circulatory assist devices in criti-
cally ill patients with compromised cardiac function.1 
This technique has been used during numerous cardiac 
surgical procedures, including after acute myocardial 
infarction and during cardiogenic shock, to both 
increase coronary blood flow and decrease left ventricu-
lar afterload.2
The concept of the IABP lies in the fact that the 
counter-pulsation caused by the pumping of the bal-
loon causes ‘volume displacement’ of blood within the 
aorta at both proximal and distal locations. This action 
leads to a potential increase in coronary blood flow 
and, in addition, can lead to improvements in systemic 
perfusion by augmentation of the intrinsic ‘Windkessel 
effect’.3 IABP treatment, therefore, enhances the ven-
tricular performance of the failing heart by facilitating 
an increase in myocardial oxygen supply in addition to 
decreasing the myocardial oxygen demand.3
Despite the evidence in favour of the IABP, recent 
guidelines from both sides of the Atlantic have down-
graded the use of IABP for cardiogenic shock from class 
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I to class IIa in American guidelines whereas, in Europe, 
IABP is now a class III treatment.4,5 Furthermore, the 
recent SHOCK-II trial demonstrated that IABP did not 
significantly reduce 12-month mortality in patients with 
cardiogenic shock complicating myocardial infarction 
undergoing early revascularization, although the self-
reported quality of life was moderate to good in survi-
vors.6 A number of recent studies, however, have 
challenged the outcomes of the SHOCK II trial, illus-
trating the fact that further work is still required to 
determine the benefit of this modality in the clinical 
situation.7,8 In addition to the SHOCK II trial data, 
widespread clinical use of the IABP had previously been 
restricted due to the fact that complications exist with 
regards to the insertion of the balloon pump which, 
despite the improvement in IABP technology, remains 
an important issue.9 Amongst the many vascular com-
plications, both limb and mesenteric ischemia are the 
most life-threatening conditions, although recent work 
from our own group has shown that reducing the length 
of the IABP catheter may reduce ischemia without alter-
ing counter-pulsation efficacy.10
In view of this knowledge, it is, therefore, important 
to understand the current data set available regarding 
the use of IABP and the types and propensity of vascular 
complications that can be induced by this intervention. 
For these reasons, the aim of this present review was to 
summarize the existing literature in terms of vascular 
complications following IABP insertion. Ultimately, 
such studies should allow us to gain further insights into 
the risk-benefit of IABP treatment, allowing clinicians 
to make more informed decisions regarding use of this 
assist device
Materials and Methods
Study selection
Studies were compiled from carrying out a literature 
search of the PubMed computerized database, using the 
following search terms: ‘IABP complications’, ‘IABP 
ischemia’, ‘IABP limb ischemia’, ‘IABP vascular compli-
cations’ and ‘visceral ischemia’. All articles published 
between 1990 and March 2016 were selected on the 
basis of the title and/or abstract. Human studies with 
more than 10 adult patients (over 18 years old) who had 
an IABP inserted due to any cardiovascular condition, 
such as cardiogenic shock, AMI or severely reduced 
LVEF (<35%), were included.
Studies describing in vivo experiments, reviews, let-
ters and case reports were excluded, Studies published 
in a language other than English or when no full text 
was available were also excluded. Furthermore, articles 
focusing on anticoagulation or antiplatelet safety in 
patients who underwent IABP or articles in which no 
complications where reported were not included.
The study selection process is outlined in Figure 1. 
When applying the search terms, 77 articles were 
identified. After applying the inclusion and exclusion 
criteria and performing an additional manual literature 
search through the references lists of published articles 
and reviews, the final data set consisted of 20 articles.
Outcomes and definitions
IABP-related complications were classified as either 
major or minor. Major complications were defined as 
complications that were lethal or required surgical treat-
ment, such as vascular injury and limb ischemia that 
were treated with thromboembolectomy, vascular repair 
or fasciotomy. Minor complications included local 
hematoma, infection and limb ischemia that was 
relieved by removal of the IABP without the need for 
further surgical intervention.11
Results
Twenty studies were included in this literature review, 
with the majority of them (n=15, 75%) being retrospec-
tive. The baseline characteristics of the 20 studies identi-
fied in this review are reported in Table 1. The majority 
of patients included in these trials had high risk factors 
for developing vascular complications, such as diabetes, 
hypertension, peripheral vascular disease and history of 
smoking. Study designs, indications, main outcomes, 
catheter size, insertion and IABP duration are summa-
rized for each article (Table 1). In summary, the total 
number of patients was 23,731; the mean age was 
63.5±4.16 years. Overall, 76.7% of the patients were 
male and the mean IABP support duration in these tri-
als ranged from 8 hours to 5.4 days.
The most frequent indications for IABP use were to 
provide support for high-risk coronary patients, cardio-
genic shock, open-heart surgery and acute myocardial 
infarction. Patients also underwent IABP implantation 
for unstable angina, myocardial revascularization and 
difficulty in weaning from cardiopulmonary bypass 
(Table 1).
The outcomes in the included studies covered both 
minor and major vascular complications related to IABP 
insertion and are summarized in Table 2.
The incidence of IABP-related vascular complica-
tions varied widely, from 0.94% to 31.1% (mean 15.1 ± 
12.5).12–18 Only one study distinguished between early 
and late complications, with early complications being 
observed in 56 patients (11%).15 In addition, only a 
small number of studies (n=5, 20%) divided vascular 
complications into major and minor. Two of them indi-
cated that major vascular complications occurred in 
6.7% and 8.1% of patients, while minor complications 
took place in 5.7% and 2.9% of cases.11,15
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The most frequent vascular complication associated 
with IABP insertion was limb ischemia which had an 
incidence ranging from 0.9% to 26.7% (mean 8.03 ± 
7.4).12–16,18–29 Arceo et al. concluded that limb ischemia 
occurred early after balloon placement and observed 
ischemia in 12 (5.7%) patients. In half of these patients, 
the ischemia was transient and resolved itself after 
removal of the IABP.28 Colyer et al. reported that only 
two patients among 37 (5.4%) experienced this compli-
cation.29
Meharwel and Thehan included 911 patients in their 
study in which 25 (2.7%) of the patients developed limb 
ischemia which needed thrombolectomy, while 3.6% of 
limb ischemia was relieved by IABP removal.11 
Christenson et al. distinguished major and minor limb 
ischemia that was observed in 6 and 12 patients, respec-
tively (overall incidence, 8.9 and 6.6%).12 Severi et  al., 
Yildirim et al. and Meisel et al. showed the lowest rate of 
limb ischemia, occurring in 4 (0.94%), 3 (2.8%) and 2 
(1.2%) patients, respectively.13,21,30 In the latter study, the 
low rate of such a complication could be due to the use 
of low-profile IABP 8Fr catheters and sheathless tech-
nique IABP.21
Treatment time is considered to be one of the major 
factors driving IABP vascular complications, with an 
increased duration of treatment leading to a higher risk 
of complications. Time duration for IABP insertion in 
the studies found ranged from 8 hours to 5.4 days. One 
study directly supports the fact that prolonged IABP 
treatment time leads to more vascular complications 
Figure 1. Study selection process.
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(vascular complications were seen in 20 patients 
(14.8%) in total).12 Boudoulas et al. also demonstrated 
that the duration of IABP assistance has a great impact 
on limb ischemia since the incidence of this complica-
tion increased dramatically when the balloon had been 
used for more than two days.18 In five studies, amputa-
tion for limb ischemia was reported at rates varying 
from 0.1 to 3.5%.14,16,19,24,28
Mesenteric ischemia is thought to be an important 
vascular complication during IABP treatment, however, 
there are actually very few studies that have directly 
assessed mesenteric ischemia complications in patients. 
The incidence appears to be quite low, with the excep-
tion of the study of Rastan et al. where the flow in the 
superior mesenteric artery was compromised in 61 out 
of a subset of 63 (87%) patients.31 In another study, it 
was reported that only one patient had mesenteric 
ischemia (0.9%); however, this did ultimately lead to 
patient death.32 For these reasons, additional studies 
should be carried out to directly assess the occurrence of 
mesenteric ischemia to determine the risk that this 
complication may confer in IABP patients. Other vascu-
lar complications are rarely mentioned in the literature; 
however, a number of studies do report on the incidence 
of pseudoaneurysm, hematoma and amputation. Limb 
ischemia was reported in two studies, with a low occur-
rence rate (1.2, 0.5%).15,21 Hematoma was described in 
six studies, with an incidence rate varying from 0.4 to 
3.9%.14,15,17,20,25,26
Bleeding or hemorrhage was mentioned in a number 
of studies, with the percentage of the incidence ranging 
from 0.4 to 27.7% (mean 5.27±8.5).18–21,25,28,29,32
In addition to analyzing the vascular complications 
themselves, the majority of studies also took into 
account the known and suspected risk factors associated 
with complications and IABP. These included periph-
eral vascular disease, hypertension, diabetes mellitus, 
smoking, gender and sheathed insertion.
Diabetes mellitus was the most common risk factor 
which occurred in 16 studies (80%) followed by periph-
eral vascular disease in 12 (60%) and hypertension in a 
total of 11 studies (55%). The least common risk factor 
was smoking which occurred in eight studies (40%).
Five studies used sheathless insertion while four used 
sheathed insertion. The rest of the studies used a combi-
nation of the two whilst three studies did not mention 
which type of balloon insertion was used.
Many studies supported the fact that sheathless inser-
tion and smaller size catheters can minimize the risk of 
vascular complications. There were two retrospective 
studies that compared modality of insertion and identi-
fied that the sheathed insertion technique is a major risk 
factor for vascular complications during the use of 
IABP.17,20 The first study showed that the incidence of 
ischemic complications was lower in the sheathless 
group (5.2%) compared with the sheathed group (12.4%, 
p = 0.001).20 However, there were no differences between 
other complications, such as bleeding and hematoma, in 
the two groups. The other study showed that vascular 
complication rate in the sheathless group was 8.8% ver-
sus 25.9% in the sheathed group (p<0.01) while hema-
toma occurred in 0.7% and 2.3%, respectively (p<0.05).17 
Together, these studies indicate that the sheathless 
approach leads to a reduced risk of complications when 
compared to the sheathed approach, although the data 
set remains limited.
Arafa et  al. pointed out that there is a significant 
decrease in the major vascular complication rate with 
IABP insertion in the last five years due to an increase in 
the use of catheters with smaller diameters.15 
Furthermore, Eltchaninoff et al. showed that there was a 
reduction in the complication profile when smaller size 
catheters were utilised.25 The catheter size in the 
included studies ranged from 7 Fr to 11.5 Fr. Some stud-
ies reported that the significant decrease in major vas-
cular complications that has occurred over previous 
years is due to the increased use of catheters with smaller 
diameters.15,22 The Benchmark IABP Registry revealed 
that the smaller 8 Fr IABP catheter might reduce the 
incidence of complications such as limb ischemia.22
The IABP catheter was inserted percutaneously 
through the femoral artery in all studies except in a few 
reports that used alternative routes, such as the trans-
thoracic approach.11,15,22
Some studies also utilised the subclavian artery 
approach which is associated with limited morbidity 
and no vascular complications were reported using this 
approach. However, additional studies are needed to 
evaluate long-term outcomes.
Complications tended to be more common in female 
patients and many studies noted that female gender 
should be considered as a risk factor. Nonetheless, only 
one study actually examined the role of gender on 
unwanted vascular events, demonstrating that female 
gender should be taken into account as a risk factor dur-
ing IABP insertion.24
Discussion
This review explores vascular complications during 
intra-aortic balloon pump assistance in the existing lit-
erature and it highlights the most common risk factors 
following IABP insertion. Identifying the occurrence 
rates of vascular complications and the major risk fac-
tors associated with deleterious effects of IABP may pre-
vent or delay the onset of complications along with 
reducing the morbidity and mortality rate.
The most common vascular complication related to 
IABP insertion is limb ischemia. The occurrence rate 
of limb ischemia increases in patients who have risk 
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factors such as peripheral vascular disease and diabetes 
mellitus. For these reasons, careful assessment of the 
aorto-femoral vascular tree should be carried out dur-
ing early diagnosis and intervention to prevent limb 
loss. It should also be noted that minor limb ischemia 
can normally be relieved by IABP removal, whilst this is 
not the case when major limb ischemia occurs, indicat-
ing that the ischemia is initially most likely caused by 
intermittent obstruction.
In fact, some patients will suffer from limb amputa-
tion as a consequences of irreversible limb ischemia due 
to IABP insertion. This is a very rare and serious com-
plication, so careful physical examination is vital to 
identify early vascular changes and treated immediately 
before they become established. Emergency revasculari-
zation via a thrombectomy can stabilize the patient to 
avoid further complications.
Bleeding and hematoma have also been reported to 
occur in several studies, with varying rates. In most 
cases, bleeding is related to the insertion site and can 
vary from mild to severe. It can lead to thrombotic com-
plications which may require transfusion or surgery. 
Many studies have stated that IABP duration time 
increases the risk of moderate and major bleeding if it 
used for a long period of time, even if it is more than two 
days. Furthermore, sheathless insertion is found not to 
be associated with high bleeding rate.
Mesenteric ischemia is a rare event, but is considered 
a potentially life-threating condition which can lead to 
serious conditions, such as gangrene of the bowel wall. 
However, only a small proportion of patients had mes-
enteric ischemia during IABP insertion in the included 
studies, due to the fact the majority of the research in 
this field has been carried out in animal studies or are 
reported in case reports, both of which were excluded in 
this review. Early diagnosis is important in any patient 
suspected of having mesenteric ischemia to prevent fur-
ther complications.
Studies from our own group have investigated the 
association between intra-aortic balloon catheter size 
and visceral flow. In a number of studies, we have com-
pared the use of a shorter balloon and compared this 
with the standard size catheters. Final results from these 
studies have concluded that the short balloon decreased 
mesenteric blood flow to a lesser extent when compared 
with the standard-size balloon, without losing IABP 
beneficial effects. In fact, it even improves visceral flows 
in comparison with the conventional IABP catheter.10,33 
Furthermore, in an additional study, Gelsomino et  al. 
investigated the effect of IABP weaning strategy on vis-
ceral flow and found that mesenteric blood flows 
decreased in both forms of weaning. These data indicate 
that the weaning strategy should not affect the occur-
rence of this complication, although further clinical 
research would be required to validate this.34
There is a lack of published information regarding 
the risk of pseudoaneurysm after IABP. The literature 
tends to only mention the number of patients without 
exploring the related risk factors. Once again, this 
should be a focus of future work
In the studies reviewed, most procedures were car-
ried out using the femoral artery for insertion of the 
IABP catheter. However, a number of studies used alter-
native approaches. The subclavian artery approach 
could be associated with a lower morbidity rate. 
However, there are some things that should be taken 
into considerations. It is more time-consuming than the 
femoral approach and, therefore, is not recommended 
in the emergency setting. Additionally, there is still a 
chance of developing vascular complications, such as 
stroke and limb ischemia, due to the fact that the bal-
loon catheter traverses the arch of the aorta. Studies, 
therefore, are needed to investigate whether this 
approach may reduce the risk of complications.
In assessing the vascular complications of IABP, sev-
eral risk factors must be taken into consideration, such 
as female gender, smaller diameter catheters, peripheral 
vascular disease and diabetes mellitus. Complications, 
in general, due to IABP tend to be more common in 
females due to the smaller size of the femoral artery, so 
whether this increased risk could be overcome by utiliz-
ing alternative access points remains to be seen.
Several studies have linked vascular complications 
with diabetes mellitus and peripheral vascular disease. 
Therefore, careful vascular assessment is required when 
inserting IABP catheters into patients with these dis-
eases to reduce the risk of vascular complication, as has 
been reported in many studies.
Sheathless insertion and smaller-size catheters can 
minimize the risk of vascular complications. It has been 
previously shown that there is a significant decrease in 
the rate of major vascular complications with IABP 
insertion in the last five years and this has been due to 
the increased use of catheters with smaller diameters. 
Moreover, the use of 6 Fr catheters has shown a great 
benefit in minimizing the risk of vascular complica-
tions, but further studies are required to cover the com-
plications risk of using a smaller-sized catheter. Finally, 
long treatment time with an IABP catheter is considered 
an independent risk factor for the development of vas-
cular complications. The longer duration of IABP sup-
port seemed to increase the risk for the of occurrence 
vascular complications.
Limitations
There are a number of limitations that should be noted 
in this review. A meta-analysis could not be performed 
due to heterogeneity of the studies as they investigated 
different outcomes, had different designs, as well as 
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variable patient populations. In addition, data for a 
number of parameters, such as IABP duration, were not 
available in some studies. Finally, in a number of studies, 
it is likely that not all of the observed complications are 
reported, therefore, it is likely we under report on the 
rates of complication during IABP.
Conclusions
In conclusion, we have carried out a literature review 
assessing the current knowledge with regards to IABP 
complications. The major vascular complications include 
limb and mesenteric ischemia as well as hemorrhage. 
However, the incidence of these complications was gen-
erally low, although there is some study-to-study vari-
ability. Furthermore, there are a number of confounding 
factors that contribute to complication rates, including 
disease status, especially with regards to diabetes melli-
tus and peripheral vascular disease. Additionally, the 
method of catheter placement and catheter size as well as 
time on pump have been shown to be detrimental in the 
incidence rate of complications.
This review provides a comprehensive overview of 
the current knowledge regarding IABP complications 
and indicates that particular care should be taken in 
IABP implantation in patients with diabetes and periph-
eral vascular disease. Furthermore, smaller and sheath-
less insertion of balloons reduce the risk of complications. 
It is hoped that these data will be used to be able to 
assess the risks that the use of IABP may confer on 
patients from various pathophysiological backgrounds.
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